Gujarat Themis Biosyn Limited (GTBL) plans to raise Rs 335 crore via a preferential issue of 82.10 lakh equity shares at Rs 408 per share. The allotment includes participation from the promoter group and external investors, subject to regulatory and shareholder approvals.
Gujarat Themis Biosyn Announces Rs 335 Crore Capital Raise
Total Issue: 82,10,786 shares | Price: Rs 408 per share
Reader Takeaway: Strong promoter participation signals internal confidence, but deal closure depends on pending shareholder and exchange approvals.
What just happened
Gujarat Themis Biosyn Limited (GTBL) has received board approval to raise approximately Rs 335 crore through a preferential allotment of equity shares. The company will issue up to 82,10,786 shares at an issue price of Rs 408 per share, which includes a securities premium of Rs 407 per share. The face value of each equity share is Rs 1.
Why this matters
This capital infusion is a strategic move to strengthen the company’s financial position. Notably, the promoter group, through Pharmaceutical Business Group (India) Limited, is participating in this round, reflecting long-term commitment to the firm's growth trajectory. The inclusion of external entities such as Special Situation India Fund and Yusuf Khwaja Hamied further broadens the shareholder base.
Allocation breakdown
The preferential issue targets five distinct investors:
- Pharmaceutical Business Group (India) Limited (Promoter): 61,27,453 shares
- Yusuf Khwaja Hamied (Non-Promoter): 2,45,100 shares
- Special Situation India Fund (Non-Promoter): 4,59,558 shares
- India Special Assets Fund III (Non-Promoter): 6,83,823 shares
- ISAF III Onshore Fund (Non-Promoter): 6,94,852 shares
Risks to watch
Investors should note that the transaction is currently subject to necessary approvals from shareholders and the stock exchanges. Any delay or failure to secure these clearances could impact the fundraising timeline. Additionally, investors should monitor upcoming disclosures regarding the specific utilization of these funds to understand how the company plans to deploy this capital.
What to track next
Watch for the official notice of the Extraordinary General Meeting (EGM) or postal ballot process, where shareholders will vote on the proposed preferential issue. Market participants will also track the final receipt of funds and subsequent announcements on operational expansion.